Skip to main content
Fig. 2 | Skeletal Muscle

Fig. 2

From: Pharmacology and macrophage modulation of HPGDS inhibitor PK007 demonstrate reduced disease severity in DMD-affected muscles of the mdx mouse model

Fig. 2

PK007-treated mice display lower PGD2 levels and increased grip strength comparable to Prednisone-treated mdx and WT mice. A PK007-treated mice display a significant decrease in PGD2-MOX concentration (pg/ml) compared to vehicle-treated mdx mice. The mean ± SEM values of blood PGD2 concentration levels are shown. An unpaired two-tailed t-test calculated biological n = 6 and p-values. **p = 0.036. B displays no significant change in mean body weight over the day 1 (postnatal day 18 [p18]) and day 10 (postnatal day 28 [p28]) treatment period for PK007 treated (green), Vehicle mdx (orange), Prednisone-treated mdx (purple) and Vehicle WT (black). C denotes a significant increase in grip strength (compared with Vehicle-mdx) for PK007 and Prednisone-treated mdx mice and WT mice on day 10. Biological n = 12 for Vehicle and PK007 mdx groups. Biological n = 6 for Prednisone-mdx and WT control mice. P values were calculated using a two-way ANOVA with Tukey’s post hoc test. **** denotes p < 0.0001

Back to article page

Skeletal Muscle

ISSN: 2044-5040

Contact us